
IKNA
Ikena Oncology
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 1
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IKNA
Ikena Oncology, Inc.
A targeted oncology company that develops precision medicines tailored to biomarker-defined patient groups
Biological Technology
03/02/2016
03/26/2021
NASDAQ Stock Exchange
10
12-31
Common stock
645 Summer Street, Suite 101, Boston, MA 02210
--
Ikena Oncology, Inc., was incorporated as a Delaware corporation on March 2, 2016 and is headquartered in Boston, Massachusetts. The company is a targeted oncology company focused on developing novel cancer therapies targeting the critical signaling pathways that drive cancer formation and spread. The company's projects focus on key cancer-driven pathways that are well validated in the scientific literature but lack approved or effective treatments, and thus have the potential to address highly unmet medical needs. By leveraging a deep understanding of discovery chemistry, translational science and patient-centered drug development, the company has established an in-depth pipeline of wholly owned and partnered projects focused on gene-defined or biomarker-driven cancers, able to target specific patient groups that the company believes are most likely to respond to the treatment of product candidates. Since commencing operations in 2016, the company has discovered or developed five oncology programs, including four product candidates in IND research or clinical development.
Company Financials
EPS
IKNA has released its 2024 Q3 earnings. EPS was reported at -0.21, versus the expected -0.27, beating expectations. The chart below visualizes how IKNA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available